*	OR T1 T2
R1	Subsumes Arg1:T6 Arg2:T7	
R2	Has_value Arg1:T4 Arg2:T6	
R3	multi Arg1:T5 Arg2:T4	
R4	AND Arg1:T1 Arg2:T5	
*	OR T10 T12 T11
R5	Subsumes Arg1:T9 Arg2:T10	
R6	AND Arg1:T15 Arg2:T16	
R7	Has_index Arg1:T14 Arg2:T17	
R8	multi Arg1:T17 Arg2:T15	
R9	Has_temporal Arg1:T9 Arg2:T14	
R10	AND Arg1:T18 Arg2:T19	
R11	Has_temporal Arg1:T18 Arg2:T20	
R12	Has_qualifier Arg1:T23 Arg2:T22	
R13	AND Arg1:T8 Arg2:T23	
R14	Has_multiplier Arg1:T28 Arg2:T27	
R15	multi Arg1:T29 Arg2:T28	
R16	Has_index Arg1:T26 Arg2:T29	
R17	Has_temporal Arg1:T23 Arg2:T25	
R18	Has_temporal Arg1:T23 Arg2:T26	
R19	AND Arg1:T21 Arg2:T23	
T1	Condition 14 22	pregnant
T2	Observation 26 39	breastfeeding
T3	Person 0 5	Women
T4	Measurement 161 189	human chorionic gonadotropin
T5	Procedure 161 205	human chorionic gonadotropin laboratory test
T6	Value 152 160	positive
T7	Value 207 216	> 5mIU/mL
T9	Condition 394 413	Tromboembolic event
T10	Condition 415 418	CVA
T11	Condition 422 447	transient ischemic attack
T12	Condition 449 452	AMI
T14	Temporal 454 523	less than 3 months prior to the intravitreal injection of bevacizumab
T15	Procedure 486 508	intravitreal injection
T16	Drug 512 523	bevacizumab
T17	Reference_point 482 523	the intravitreal injection of bevacizumab
T18	Condition 536 552	hypersensitivity
T19	Drug 557 568	bevacizumab
T20	Temporal 525 532	History
T8	Person 219 224	Women
T21	Condition 228 251	child bearing potential
T22	Qualifier 271 280	effective
T23	Procedure 281 294	contraception
T25	Temporal 307 323	during the trial
T26	Temporal 328 392	for at least 28 days following the last dose of study medication
T27	Multiplier 363 372	last dose
T28	Drug 376 392	study medication
T29	Reference_point 359 392	the last dose of study medication
